{"entity":{"type":"insider","cik":"0002011869","url":"/insider/0002011869","json_url":"/insider/0002011869.json","name":"Kaiser Peter","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":8,"n_filings":8,"first":"2024-11-27","last":"2026-05-28","span_basis":"filed_date"},"name_variants":[{"name":"Kaiser Peter","source":"filing","n_filings":8,"first_seen":"2024-11-27","last_seen":"2026-05-28"}],"transactions":[{"id":6071382,"accession":"0001104659-26-067483","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-26-067483","line_url":"/filing/0001104659-26-067483#line-1","is_derivative":false,"issuer_cik":"0001393434","issuer_name":"OCULAR THERAPEUTIX, INC","issuer_ticker":"OCUL","issuer_name_source":null,"issuer_url":"/issuer/0001393434","owner_cik":"0002011869","owner_name":"Kaiser Peter","owner_display_name":"Kaiser Peter","owner_url":"/insider/0002011869","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2967.0,"shares_display":"2,967","price_per_share":8.2,"price_display":"8.20","price_state":"stated","total_value":24329.4,"total_display":"24,329.40","total_whole":"24,329","shares_owned_after":266141.0,"shares_owned_after_display":"266,141","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-26","filed_date":"2026-05-28","scope":"insider"},{"id":5976140,"accession":"0001104659-26-019804","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-26-019804","line_url":"/filing/0001104659-26-019804#line-1","is_derivative":false,"issuer_cik":"0001393434","issuer_name":"OCULAR THERAPEUTIX, INC","issuer_ticker":"OCUL","issuer_name_source":null,"issuer_url":"/issuer/0001393434","owner_cik":"0002011869","owner_name":"Kaiser Peter","owner_display_name":"Kaiser Peter","owner_url":"/insider/0002011869","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2810.0,"shares_display":"2,810","price_per_share":8.28,"price_display":"8.28","price_state":"stated","total_value":23266.8,"total_display":"23,266.80","total_whole":"23,267","shares_owned_after":269108.0,"shares_owned_after_display":"269,108","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-23","filed_date":"2026-02-25","scope":"insider"},{"id":4764808,"accession":"0001104659-25-116422","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-116422","line_url":"/filing/0001104659-25-116422#line-1","is_derivative":false,"issuer_cik":"0001393434","issuer_name":"OCULAR THERAPEUTIX, INC","issuer_ticker":"OCUL","issuer_name_source":null,"issuer_url":"/issuer/0001393434","owner_cik":"0002011869","owner_name":"Kaiser Peter","owner_display_name":"Kaiser Peter","owner_url":"/insider/0002011869","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3007.0,"shares_display":"3,007","price_per_share":12.02,"price_display":"12.02","price_state":"stated","total_value":36144.14,"total_display":"36,144.14","total_whole":"36,144","shares_owned_after":191433.0,"shares_owned_after_display":"191,433","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-24","filed_date":"2025-11-26","scope":"insider"},{"id":4799956,"accession":"0001104659-25-097165","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-097165","line_url":"/filing/0001104659-25-097165#line-1","is_derivative":false,"issuer_cik":"0001393434","issuer_name":"OCULAR THERAPEUTIX, INC","issuer_ticker":"OCUL","issuer_name_source":null,"issuer_url":"/issuer/0001393434","owner_cik":"0002011869","owner_name":"Kaiser Peter","owner_display_name":"Kaiser Peter","owner_url":"/insider/0002011869","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9653.0,"shares_display":"9,653","price_per_share":11.03,"price_display":"11.03","price_state":"stated","total_value":106472.59,"total_display":"106,472.59","total_whole":"106,473","shares_owned_after":194440.0,"shares_owned_after_display":"194,440","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-02","filed_date":"2025-10-06","scope":"insider"},{"id":5162833,"accession":"0001104659-25-084117","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-084117","line_url":"/filing/0001104659-25-084117#line-1","is_derivative":false,"issuer_cik":"0001393434","issuer_name":"OCULAR THERAPEUTIX, INC","issuer_ticker":"OCUL","issuer_name_source":null,"issuer_url":"/issuer/0001393434","owner_cik":"0002011869","owner_name":"Kaiser Peter","owner_display_name":"Kaiser Peter","owner_url":"/insider/0002011869","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3011.0,"shares_display":"3,011","price_per_share":12.04,"price_display":"12.04","price_state":"stated","total_value":36252.44,"total_display":"36,252.44","total_whole":"36,252","shares_owned_after":204093.0,"shares_owned_after_display":"204,093","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-25","filed_date":"2025-08-27","scope":"insider"},{"id":5043586,"accession":"0001104659-25-053091","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-053091","line_url":"/filing/0001104659-25-053091#line-1","is_derivative":false,"issuer_cik":"0001393434","issuer_name":"OCULAR THERAPEUTIX, INC","issuer_ticker":"OCUL","issuer_name_source":null,"issuer_url":"/issuer/0001393434","owner_cik":"0002011869","owner_name":"Kaiser Peter","owner_display_name":"Kaiser Peter","owner_url":"/insider/0002011869","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2974.0,"shares_display":"2,974","price_per_share":7.17,"price_display":"7.17","price_state":"stated","total_value":21323.58,"total_display":"21,323.58","total_whole":"21,324","shares_owned_after":207104.0,"shares_owned_after_display":"207,104","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-23","filed_date":"2025-05-27","scope":"insider"},{"id":4029711,"accession":"0001104659-25-017564","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-017564","line_url":"/filing/0001104659-25-017564#line-1","is_derivative":false,"issuer_cik":"0001393434","issuer_name":"OCULAR THERAPEUTIX, INC","issuer_ticker":"OCUL","issuer_name_source":null,"issuer_url":"/issuer/0001393434","owner_cik":"0002011869","owner_name":"Kaiser Peter","owner_display_name":"Kaiser Peter","owner_url":"/insider/0002011869","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3009.0,"shares_display":"3,009","price_per_share":6.87,"price_display":"6.87","price_state":"stated","total_value":20671.83,"total_display":"20,671.83","total_whole":"20,672","shares_owned_after":210078.0,"shares_owned_after_display":"210,078","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-24","filed_date":"2025-02-26","scope":"insider"},{"id":2147250,"accession":"0001104659-24-123413","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-24-123413","line_url":"/filing/0001104659-24-123413#line-1","is_derivative":false,"issuer_cik":"0001393434","issuer_name":"OCULAR THERAPEUTIX, INC","issuer_ticker":"OCUL","issuer_name_source":null,"issuer_url":"/issuer/0001393434","owner_cik":"0002011869","owner_name":"Kaiser Peter","owner_display_name":"Kaiser Peter","owner_url":"/insider/0002011869","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2897.0,"shares_display":"2,897","price_per_share":9.01,"price_display":"9.01","price_state":"stated","total_value":26101.97,"total_display":"26,101.97","total_whole":"26,102","shares_owned_after":213087.0,"shares_owned_after_display":"213,087","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-25","filed_date":"2024-11-27","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":8,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":8,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":8},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001393434","name":"OCULAR THERAPEUTIX, INC","url":"/issuer/0001393434","role":"Officer (Chief Development Officer)","n_filings":8,"first_seen":"2024-11-27","last_seen":"2026-05-28"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0002011869","retrieved_at":"2026-08-22T20:20:32+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}